Yes, progestogen is absolutely required for endometrial protection in perimenopausal women on estrogen replacement therapy, regardless of whether they are still cycling.
In women with a uterus receiving estrogen therapy, a progestogen must be added to prevent endometrial hyperplasia and cancer 1. The fact that a perimenopausal woman continues to have menstrual cycles does not eliminate the need for progestogen protection—the exogenous estrogen exposure still stimulates the endometrium and requires opposition.
Why Progestogen is Non-Negotiable
The evidence is unequivocal: unopposed estrogen therapy increases the risk of endometrial hyperplasia at all doses and durations between one and three years 2. This risk exists whether the woman is:
- Still cycling naturally
- In perimenopause with irregular cycles
- Fully postmenopausal
The endogenous progesterone production during her own menstrual cycles (if ovulatory) does not provide adequate protection against the additional estrogen load from hormone replacement therapy.
Recommended Progestogen Regimens
For a perimenopausal woman who is still cycling, the combined sequential regimen is preferred 1:
- Estrogen for 20-25 days per month
- Progestogen for 12-15 days each month
This approach is specifically recommended for recently menopausal women who are prone to breakthrough bleeding during the first year or two of therapy 1.
Specific Dosing Options That Provide Adequate Protection:
Oral options:
- Micronized progesterone 200 mg/day for 12-14 days/month (sequential) 3
- Norethisterone acetate (NETA) minimum 1 mg daily
- Medroxyprogesterone acetate (MPA) minimum 1.5 mg daily 2
Alternative routes:
- Vaginal micronized progesterone 4% gel (45 mg/day) for at least 10 days/month 3
- Transdermal progestogen via patch 1
- Levonorgestrel intrauterine device (though note one observational study reported higher breast cancer incidence) 1
Critical Pitfall to Avoid
Do not assume that ongoing menstrual cycles provide sufficient endometrial protection. The woman's endogenous progesterone production (if she's still ovulating) addresses only her baseline endometrial stimulation from her own estrogen, not the additional exogenous estrogen from hormone replacement therapy. The cumulative estrogen exposure requires dedicated progestogen opposition 4.
Continuous vs Sequential Regimens
While sequential regimens are preferred initially for cycling perimenopausal women, you could alternatively use a combined continuous regimen (both estrogen and progestogen daily) 1. However, this may cause more irregular bleeding in women who are still having periods, which is why sequential therapy is typically the better initial choice for this population.
The bottom line: progestogen protection is mandatory for any woman with a uterus receiving systemic estrogen therapy, regardless of menopausal status or cycling pattern 1, 2.